A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon.
Author: BENJAMIN MUELLER
Advertisements
{
"slotId": "6845006044",
"unitType": "responsive",
"resize": "auto"
}